Drug intelligence / Profile preview

OP-2024-C

Development stage: Unknown
Lead developer: Ohara Pharmaceutical
Administration: Oral

Overview

**OP-2024-C** is an orally administered investigational antiparkinsonian drug product developed by **Ohara Pharmaceutical** for advanced Parkinson's disease in patients with clinically significant OFF time despite treatment with immediate-release levodopa/carbidopa. In the completed Japanese Phase II OP-2024-003 trial, OP-2024-C was evaluated as single and multiple oral doses against levodopa/carbidopa hydrate tablets for safety, pharmacokinetics, PK-PD relationships, and efficacy. Its active-ingredient composition, release characteristics, and molecular mechanism have not been publicly disclosed in the identified official registry record. ([jrct.mhlw.go.jp](https://jrct.mhlw.go.jp/en-latest-detail/jRCT2021230019))

Beyond the preview

Go deeper on OP-2024-C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OP-2024-C.

Explore the full profile